Evidence map›Paper›PMID 41057497›Full record

ArticleScientific reports2025

Immunocompetent C57BL/6 syngeneic mouse ovarian cancer models with defined genetic alterations.

Hasmik Agadjanian, Beth Y Karlan, Christine S Walsh, Sandra Orsulic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hasmik AgadjanianWomen's Cancer Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Beth Y KarlanDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Christine S WalshWomen's Cancer Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sandra OrsulicDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. sorsulic@mednet.ucla.edu.

Funding

BLRD VA I01 BX006020Congressionally Directed Medical Research Programs DAMD-OC080179Congressionally Directed Medical Research Programs,United States HT9425-24-1-0193U.S. Department of Veterans Affairs BX006020
6 · The paper itself

Abstract

Ovarian cancer remains one of the deadliest gynecologic cancers globally, with limited progress in early detection and treatment. Syngeneic mouse ovarian cancer cell lines, derived from immunocompetent mice, have become essential tools for studying ovarian cancer biology and assessing novel therapies. With the rise of immunotherapies such as immune checkpoint inhibitors and cancer vaccines, these syngeneic models are critical for preclinical studies within the context of an intact immune system. The availability of diverse syngeneic ovarian cancer models ensures that research captures the full spectrum of human ovarian cancer variability, including variations in genetic mutations, signaling pathways, tumor antigenicity, and molecular subtypes. Here, we report the development and characterization of a panel of syngeneic ovarian cancer cell lines with defined combinations of initiating genetic alterations, such as TP53 deficiency, Hras mutation, and overexpression of Myc and Cyclin E. The Introduction of one or two oncogene drivers resulted in TP53-/- cell transformation and growth in nude and immunocompetent syngeneic C57BL/6 mice. Intraperitoneal tumors grew with high penetrance and had a wide metastatic distribution and concurrent ascites, which closely resembles the clinical picture of human serous ovarian cancer.

Indexed as

Ovarian NeoplasmsAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansImmunocompetenceMiceMice, Inbred C57BLMice, NudeMutationProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)Trp53 protein, mouseTumor Suppressor Protein p53Cyclin EImmunogenic cell deathMouse models of cancerOvarian cancerp53Syngeneic cancer cell lines

Identifiers

PMID41057497
PMCPMC12504517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.